NASDAQ
No price data available for this timeframe.
Beam Therapeutics Inc. (BEAM) has a free cash flow growth of -50.24% as of Friday, May 29, 2026. This represents a 985.55% decrease compared to its 12-month average of -4.63%. Free cash flow growth tracks the year-over-year percentage change in cash generated after capital expenditures.